Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

By R. Lago, Premranjan P. Singh, R. Nesto. The Lancet, 2007

688 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Pathophysiology of human visceral obesity: an update. (2013, background): “However, the side effects of TZDs must be taken into account, specifically an increased risk of heart failure, which has been closely examined (220, 289, 399, 535, 643).”
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012, positive): “TZDs should be avoided [117, 118].”
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial (2016, background): “Furthermore, specific glucose-lowering medications have not been shown to improve heart failure outcomes and some may actually have deleterious effects.(5) –8”
Inflammatory Mechanisms in the Regulation of Insulin Resistance (2008, background): “Recently some caution on this drug class has been raised, as metaanalyses demonstrated an increased rate of cardiovascular events in certain patient groups (123,124).”